Cargando…

Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma

OBJECTIVE: Transarterial chemoembolization is the treatment of choice for intermediate-stage hepatocellular carcinoma. However, there are no clear data supporting transarterial chemoembolization vs. transarterial embolization or regarding the best chemotherapeutic agent, which may suggest a preponde...

Descripción completa

Detalles Bibliográficos
Autores principales: Monsignore, Lucas Moretti, Elias-Junior, Jorge, Muglia, Valdair Francisco, Teixeira, Andreza Correa, Mente, Enio David, de Lourdes Candolo Martinelli, Ana, Abud, Daniel Giansante
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676315/
https://www.ncbi.nlm.nih.gov/pubmed/26735217
http://dx.doi.org/10.6061/clinics/2015(12)04
_version_ 1782405155718692864
author Monsignore, Lucas Moretti
Elias-Junior, Jorge
Muglia, Valdair Francisco
Teixeira, Andreza Correa
Mente, Enio David
de Lourdes Candolo Martinelli, Ana
Abud, Daniel Giansante
author_facet Monsignore, Lucas Moretti
Elias-Junior, Jorge
Muglia, Valdair Francisco
Teixeira, Andreza Correa
Mente, Enio David
de Lourdes Candolo Martinelli, Ana
Abud, Daniel Giansante
author_sort Monsignore, Lucas Moretti
collection PubMed
description OBJECTIVE: Transarterial chemoembolization is the treatment of choice for intermediate-stage hepatocellular carcinoma. However, there are no clear data supporting transarterial chemoembolization vs. transarterial embolization or regarding the best chemotherapeutic agent, which may suggest a preponderant role of ischemia over chemotherapeutic action. This study sought to evaluate the radiological response and outcome of transarterial chemoembolization modified by n-butyl cyanoacrylate addition compared to conventional transarterial chemoembolization in hepatocellular carcinoma patients. MATERIALS AND METHODS: A retrospective review identified forty-seven patients who underwent modified chemoembolization and thirty-three who underwent conventional chemoembolization between June 2006 and December 2011. The radiological response was reassessed using the modified Response Evaluation Criteria in Solid Tumors. The sustained complete response, time to progression and overall survival rates were also analyzed. RESULTS: Complete response rates were significantly higher in patients who had undergone modified chemoembolization compared to those who had undergone conventional treatment (61.7% and 24.3%, respectively; p<0.001). The rate of sustained complete response was significantly higher in the modified chemoembolization group compared to the conventional chemoembolization group (median of 236 and 37 days, respectively; p<0.001). Time to progression was significantly higher in the modified chemoembolization group compared to the conventional chemoembolization group (median of 424 and 201 days, respectively; p=0.042). Overall survival rates revealed no difference between patients who received modified chemoembolization and conventional chemoembolization (median of 483 and 399 days, respectively; p=0.316). CONCLUSION: Transarterial chemoembolization modified by n-butyl cyanoacrylate addition was superior to conventional transarterial chemoembolization in terms of the radiological response in the first imaging control. Although the sustained complete response and time to progression rates were higher for the modified chemoembolization group, no differences in overall survival rates were observed.
format Online
Article
Text
id pubmed-4676315
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-46763152016-01-04 Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma Monsignore, Lucas Moretti Elias-Junior, Jorge Muglia, Valdair Francisco Teixeira, Andreza Correa Mente, Enio David de Lourdes Candolo Martinelli, Ana Abud, Daniel Giansante Clinics (Sao Paulo) Clinical Science OBJECTIVE: Transarterial chemoembolization is the treatment of choice for intermediate-stage hepatocellular carcinoma. However, there are no clear data supporting transarterial chemoembolization vs. transarterial embolization or regarding the best chemotherapeutic agent, which may suggest a preponderant role of ischemia over chemotherapeutic action. This study sought to evaluate the radiological response and outcome of transarterial chemoembolization modified by n-butyl cyanoacrylate addition compared to conventional transarterial chemoembolization in hepatocellular carcinoma patients. MATERIALS AND METHODS: A retrospective review identified forty-seven patients who underwent modified chemoembolization and thirty-three who underwent conventional chemoembolization between June 2006 and December 2011. The radiological response was reassessed using the modified Response Evaluation Criteria in Solid Tumors. The sustained complete response, time to progression and overall survival rates were also analyzed. RESULTS: Complete response rates were significantly higher in patients who had undergone modified chemoembolization compared to those who had undergone conventional treatment (61.7% and 24.3%, respectively; p<0.001). The rate of sustained complete response was significantly higher in the modified chemoembolization group compared to the conventional chemoembolization group (median of 236 and 37 days, respectively; p<0.001). Time to progression was significantly higher in the modified chemoembolization group compared to the conventional chemoembolization group (median of 424 and 201 days, respectively; p=0.042). Overall survival rates revealed no difference between patients who received modified chemoembolization and conventional chemoembolization (median of 483 and 399 days, respectively; p=0.316). CONCLUSION: Transarterial chemoembolization modified by n-butyl cyanoacrylate addition was superior to conventional transarterial chemoembolization in terms of the radiological response in the first imaging control. Although the sustained complete response and time to progression rates were higher for the modified chemoembolization group, no differences in overall survival rates were observed. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2015-12 2015-12 /pmc/articles/PMC4676315/ /pubmed/26735217 http://dx.doi.org/10.6061/clinics/2015(12)04 Text en Copyright © 2015 CLINICS http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Science
Monsignore, Lucas Moretti
Elias-Junior, Jorge
Muglia, Valdair Francisco
Teixeira, Andreza Correa
Mente, Enio David
de Lourdes Candolo Martinelli, Ana
Abud, Daniel Giansante
Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma
title Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma
title_full Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma
title_fullStr Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma
title_full_unstemmed Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma
title_short Addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma
title_sort addition of n-butyl cyanoacrylate to classic transarterial chemoembolization may improve the radiological response in patients with hepatocellular carcinoma
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676315/
https://www.ncbi.nlm.nih.gov/pubmed/26735217
http://dx.doi.org/10.6061/clinics/2015(12)04
work_keys_str_mv AT monsignorelucasmoretti additionofnbutylcyanoacrylatetoclassictransarterialchemoembolizationmayimprovetheradiologicalresponseinpatientswithhepatocellularcarcinoma
AT eliasjuniorjorge additionofnbutylcyanoacrylatetoclassictransarterialchemoembolizationmayimprovetheradiologicalresponseinpatientswithhepatocellularcarcinoma
AT mugliavaldairfrancisco additionofnbutylcyanoacrylatetoclassictransarterialchemoembolizationmayimprovetheradiologicalresponseinpatientswithhepatocellularcarcinoma
AT teixeiraandrezacorrea additionofnbutylcyanoacrylatetoclassictransarterialchemoembolizationmayimprovetheradiologicalresponseinpatientswithhepatocellularcarcinoma
AT menteeniodavid additionofnbutylcyanoacrylatetoclassictransarterialchemoembolizationmayimprovetheradiologicalresponseinpatientswithhepatocellularcarcinoma
AT delourdescandolomartinelliana additionofnbutylcyanoacrylatetoclassictransarterialchemoembolizationmayimprovetheradiologicalresponseinpatientswithhepatocellularcarcinoma
AT abuddanielgiansante additionofnbutylcyanoacrylatetoclassictransarterialchemoembolizationmayimprovetheradiologicalresponseinpatientswithhepatocellularcarcinoma